Slide 1: Optomed Q1 2023
Optomed Q1 2023 5th May 2023 Seppo Kopsala, CEO Sakari Knuutti, CFO
Slide 2: Q1/2023 Highlights
Q1/2023 Highlights 1. 2. 3. Software segment Devices segment Clinical trial: 20+ % growth track impacted by lack of data collection continued large OEM orders continues with no hiccups
Slide 3: Q1/2023 Key Figures
Q1/2023 Key Figures REVENUE GROWTH WAS DRIVEN BY OUR SOFTWARE SEGMENT THAT GREW 20.5% Q1/2023 Q1/2022 Change Revenue 3,478 3,214 8.2% Gross profit 1) 2,476 2,190 13.1% Gross margin 2) 71.2% 68.1% 2.1 pps EBITDA -513 -937 45.2% EBITDA margin -14.8% -29.2% 14.4 pps Net profit / loss -1,157 -1,370 15.5
Slide 4: Segment highlights
Segment highlights OPT@MED
Slide 5: Devices Segment Q1-2023
Devices Segment Q1-2023 DEVICES’ REVENUE DECLINED DUE TO LACK OF MAJOR OEM ORDERS Q1/2023 Q1/2022 Change Revenue declined 16.5 % due to 1. lack of major OEM orders during the quarter Revenue 888 1,065 -16.5% Gross profit 559 641 -12.8% The US and distributors sales channels 2. performed well Gross m
Slide 6: Software Segment Q1-2023
Software Segment Q1-2023 OUR SOFTWARE SEGMENT HAD ANOTHER VERY GOOD QUARTER Q1/2023 Q1/2022 Change Revenue increased by 20.5 % 1. and EBITDA margin improved significantly Revenue 2,590 2,150 20.5% The increase was driven by very Gross profit 1,917 1,549 23.8% 2. strong performance of the healthcare
Slide 7: Cash Flow
Cash Flow CASH FLOW FROM OPERATING ACTIVITIES IMPROVED Q1 2023 Q1 2022 Loss for the financial year -1,157 -1,370 Cash flows before change -471 -893 in net working capital • Net cash from operating activities was 440 negative Change in net working capital 58 240 Cash flows before finance items -413 -
Slide 8: New Business Model
New Business Model SIGNIFICANT RECURRING REVENUE OPPORTUNITY IN THE US Complete Solution Recurring Revenue Model Customer Benefits Newly established From product sales to Solution leased, not reimbursement complete screening No initial investments code CPT 92229 sold – enables solutions with diagnos
Slide 9: Optomed's mission is to prevent blindness by improving access to eye screening globally
Optomed’s mission is to prevent blindness by improving access to eye screening globally Bringing AI-integrated Expansion into new Opening new customer health screening to the geographical markets segments: primary care market
Slide 10: Appendix
Appendix
Slide 11: Devices Segment: Key Financials FY 2022
Devices Segment: Key Financials FY 2022 1-12/2022 1-12/2021 Change % Revenue 5,398 5,839 -7.6 % Gross profit 3,738 4,139 -9.7 % Gross margin 69.3 % 70.9 % EBITDA -670 -1,014 33.9 % EBITDA margin -12.4 % -17.4 %
Slide 12: Software Segment: Key Financials FY 2022
Software Segment: Key Financials FY 2022 1-12/2022 1-12/2021 Change % Revenue 9,263 9,011 2.8 % Gross profit 6,330 6,420 -1.4 % Gross margin 68.3 % 71.2 % EBITDA 2,079 1,855 12.1 % EBITDA margin 22.4 % 20.6 %
Slide 13: Cash Flow: FY 2022
Cash Flow: FY 2022 1-12/2022 1-12/2021 Loss for the financial year -5,472 -4,249 Cash flows before change in net working capital -2,479 -1,579 Change in net working capital 308 -1,233 Cash flows before finance items -2,171 -2,811 Cash flows from finance items -199 -129 Net cash from operating activi
Slide 14: Balance Sheet
Balance Sheet 31 March 2023 31 December 2022 • Equity ratio of 64.9 (65.0) ASSETS percent Goodwill 4,256 4,256 Development costs 6,849 6,562 • Total borrowings of EUR 4.9 Other intangible assets 1,992 2,077 Total intangible assets 13,096 12,895 (5.3) million Total tangible assets 2,162 2,315 Total n